Kunming Longjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 13, 2020 at 07:20 am EDT
Share
Kunming Longjin Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 275.292 million compared to CNY 335.984 million a year ago. Operating loss was CNY 21.954 million compared to operating Income of CNY 16.695 million a year ago. Net loss was CNY 23.107 million compared to net income of CNY 13.870 million a year ago. Basic loss per share from continuing operations was CNY 0.0577 compared to basic earnings per share from continuing operations of CNY 0.0346 a year ago.
Kunming Longjin Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, manufacture and sales of natural botanical and chemical lyophilized powder injection. The Company's products cover traditional Chinese medicine, biochemical medicine and chemical medicine, which including cardio-cerebral vascular medicine, digestive system medicine, immune system medicine, vitamins, mineral enteral and parenteral nutrition medicines. The main products of which is breviscapine injection. The Company conducts its businesses primarily within the domestic market.